Life Scientist > Biotechnology

Biota aims to reclaim position after flat half-year

04 March, 2002 by Tanya Hollis

Biota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million.


Medical devices network takes shape

01 March, 2002 by Daniella Goldberg

A new network for the medical device industry is gearing up for launch.


Plant breeders to get access to genetic info

01 March, 2002 by Tanya Hollis

Plant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government.


GroPep offloads IP to concentrate on protein pharma

01 March, 2002 by Tanya Hollis

South Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest.


Cash injection boosts Amrad R&D program

01 March, 2002 by Tanya Hollis

Drug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.


R&D spend dominates BresaGen half-year

28 February, 2002 by Daniella Goldberg

Australian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago.


AgVic's genetic hens join the elites

28 February, 2002 by Tanya Hollis

Agriculture Victoria's 40-year bantamised hen project has entered the commercialisation phase, beginning a joint research deal with an elite international breeder.


Axon releases new drug discovery tool

28 February, 2002 by Tanya Hollis

A screening instrument that enables drug company technicians to run parallel tests has been released by Melbourne-based company Axon Instruments (ASX: AXN).


Shellfish gene helps Brisbane biotech

27 February, 2002 by Pete Young

Brisbane biotech business Xenome Ltd is moving closer to human trials with a pain-killing molecule derived from the venom of a marine shellfish.


MicroMedical's human heart trials imminent

26 February, 2002 by Tanya Hollis

Australia's first artificial hearts are to be implanted in human patients within weeks, according to the developer.


New IMB research targets cystic fybrosis

25 February, 2002 by Pete Young

Queensland bioresearchers have discovered a promising method for treating a common bacterial infection afflicting cystic fibrosis patients.


No GM wheat here: Monsanto

22 February, 2002 by Melissa Trudinger

The Australian branch of agricultural biotechnology giant Monsanto today refuted reports that its herbicide resistant genetically modified wheat seed was taking longer than expected to gain approval in the US.


Heavyweight board a coup for start-up Farmacule

22 February, 2002 by Pete Young

Queensland molecular farming start-up Farmacule Bioindustries has scored a mini-coup by appointing ex-Dow Chemical heavyweight Dr Paul Zorner to its board.


Peptech stands by directors' remuneration

21 February, 2002 by Daniella Goldberg

The Australian Shareholders Association (ASA) has clashed with Sydney biotech company Peptech over the company's remuneration of non-executive board members.


Xenotransplants: not quite around the corner

21 February, 2002 by Daniella Goldberg

Pig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd